Little Green Pharma Past Earnings Performance
Past criteria checks 0/6
Little Green Pharma's earnings have been declining at an average annual rate of -10.2%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 47.7% per year.
Key information
-10.2%
Earnings growth rate
12.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 47.7% |
| Return on equity | -13.0% |
| Net Margin | -32.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Improved Revenues Required Before Little Green Pharma Ltd (ASX:LGP) Shares Find Their Feet
Nov 19
The Market Doesn't Like What It Sees From Little Green Pharma Ltd's (ASX:LGP) Revenues Yet As Shares Tumble 27%
Jun 30Estimating The Fair Value Of Little Green Pharma Ltd (ASX:LGP)
Jun 17Little Green Pharma (ASX:LGP) Has Debt But No Earnings; Should You Worry?
Mar 05Not Many Are Piling Into Little Green Pharma Ltd (ASX:LGP) Just Yet
Nov 01A Look At The Intrinsic Value Of Little Green Pharma Ltd (ASX:LGP)
May 08Statutory Earnings May Not Be The Best Way To Understand Little Green Pharma's (ASX:LGP) True Position
Sep 06What Type Of Shareholders Make Up Little Green Pharma Ltd's (ASX:LGP) Share Registry?
Feb 11
Revenue & Expenses Breakdown
How Little Green Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 29 | -9 | 16 | 5 |
| 30 Jun 24 | 27 | -9 | 16 | 5 |
| 31 Mar 24 | 26 | -8 | 16 | 5 |
| 31 Dec 23 | 26 | -6 | 23 | 1 |
| 30 Sep 23 | 25 | -3 | 23 | -1 |
| 30 Jun 23 | 22 | -6 | 21 | 0 |
| 31 Mar 23 | 20 | -9 | 20 | 1 |
| 31 Mar 22 | 14 | -24 | 26 | 4 |
| 31 Dec 21 | 11 | 13 | 16 | 1 |
| 30 Sep 21 | 9 | 18 | 12 | 0 |
| 30 Jun 21 | 7 | 22 | 8 | -2 |
| 31 Mar 21 | 6 | 9 | 8 | -1 |
| 31 Dec 20 | 5 | -3 | 7 | -1 |
| 30 Sep 20 | 4 | -6 | 7 | 0 |
| 30 Jun 20 | 2 | -9 | 8 | 0 |
| 31 Mar 20 | 2 | -9 | 8 | 0 |
| 31 Dec 19 | 1 | -9 | 7 | 1 |
| 30 Sep 19 | 1 | -7 | 6 | 0 |
| 30 Jun 19 | 0 | -6 | 5 | 0 |
| 30 Jun 18 | 0 | -4 | 2 | 0 |
| 30 Jun 17 | 0 | 0 | 0 | 0 |
Quality Earnings: LGP is currently unprofitable.
Growing Profit Margin: LGP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LGP is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare LGP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26.6%).
Return on Equity
High ROE: LGP has a negative Return on Equity (-12.99%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 17:21 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Little Green Pharma Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cameron Bell | Canaccord Genuity |